ANDISIK
$SPPI, began Phase 2 study evaluating : ZEVALIN + rituximab in combination with motexafin gadolinium (MGd) for non-Hodgkin's lymphoma.
- About
- Help
- Blog
- Jobs
- Press
- Tools
- Mobile
- Developers
- House Rules
- For Public Companies
- For Market Professionals
-
- Terms
- Privacy
- Disclaimer
- Market Quotes provided by Xignite © 2013 StockTwits, Inc.